Alimera Sciences, Inc. (NASDAQ:ALIM) Given a $3.00 Price Target by Cowen and Company Analysts
Alimera Sciences, Inc. (NASDAQ:ALIM) has been given a $3.00 target price by analysts at Cowen and Company in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cowen and Company’s price target indicates a potential upside of 91.08% from the stock’s current price.
ALIM has been the topic of a number of other reports. Rodman & Renshaw assumed coverage on shares of Alimera Sciences in a research report on Thursday, April 27th. They issued a “buy” rating and a $4.00 price target on the stock. HC Wainwright set a $5.00 price target on shares of Alimera Sciences and gave the stock a “buy” rating in a research report on Tuesday, July 11th. Zacks Investment Research upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. Finally, ValuEngine downgraded shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $3.38.
Alimera Sciences (NASDAQ ALIM) traded up 4.67% on Thursday, reaching $1.57. 382,253 shares of the company’s stock were exchanged. The firm’s market capitalization is $101.89 million. The stock’s 50 day moving average price is $1.42 and its 200 day moving average price is $1.38. Alimera Sciences has a 1-year low of $1.03 and a 1-year high of $2.40.
Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million during the quarter, compared to the consensus estimate of $10.20 million. During the same quarter in the previous year, the business posted ($0.17) earnings per share. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. On average, analysts expect that Alimera Sciences will post ($0.21) earnings per share for the current year.
A number of hedge funds have recently modified their holdings of the stock. Kennedy Capital Management Inc. purchased a new stake in shares of Alimera Sciences during the first quarter valued at $467,000. JW Asset Management LLC increased its stake in shares of Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares in the last quarter. Finally, KCG Holdings Inc. increased its stake in shares of Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares in the last quarter. Hedge funds and other institutional investors own 43.58% of the company’s stock.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.